— Action date set for August 22, 2018 —

STAINES-UPON-THAMES, UK I February 23, 2018 I Mallinckrodt plc (NYSE: MNK), a leading global specialty pharmaceutical company, today announced the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA)  seeking approval of its recently acquired developmental product stannsoporfin. If approved, the drug is expected to become the first and only pharmacologic option in the U.S. indicated for treatment of neonates at risk for developing severe hyperbilirubinemia, or severe jaundice.

Under the Prescription Drug User Fee Act (PDUFA), the FDA has set its action date to respond to the NDA as August 22, 2018.  The agency previously granted its Fast Track status to stannsoporfin. The Fast Track designation is a process designed to facilitate the development, and expedite the review of drugs to treat serious conditions and fill an unmet medical need1.

“We are pleased the FDA has accepted our application,” said Steve Romano, M.D., Chief Scientific Officer and Executive Vice President of Mallinckrodt. “We look forward to working with the agency in the coming months on the potential approval of stannsoporfin as a new treatment option for thousands of infants at risk for developing severe jaundice who have an unmet medical need.”

Neonatal jaundice is a common condition in neonates that is associated with the yellowing of the skin and the whites of the eyes, typically in the first few days after birth. In most cases, it does not require treatment; however, elevated bilirubin levels in the blood (hyperbilirubinemia) can be toxic and may potentially lead to neurologic complications, including encephalopathy or irreversible brain damage. Currently, phototherapy is used to help the body clear bilirubin and bring levels down.

Stannsoporfin is a heme oxygenase inhibitor under investigation for its potential to reduce the production of bilirubin in infants at risk for severe neonatal jaundice. The safety and effectiveness of stannsoporfin have not yet been established by the FDA.

Mallinckrodt is a global business that develops, manufactures, markets and distributes specialty pharmaceutical products and therapies. Areas of focus include autoimmune and rare diseases in specialty areas like neurology, rheumatology, nephrology, pulmonology and ophthalmology; immunotherapy and neonatal respiratory critical care therapies; analgesics and gastrointestinal products. The company’s core strengths include the acquisition and management of highly regulated raw materials and specialized chemistry, formulation and manufacturing capabilities. The company’s Specialty Brands segment includes branded medicines and its Specialty Generics segment includes specialty generic drugs, active pharmaceutical ingredients and external manufacturing. To learn more about Mallinckrodt, visit www.mallinckrodt.com.

SOURCE: Mallinckrodt